Q1 · CROSS-FIELD
Article
Author: Hübner, Marc P. ; Gusovsky, Fabian ; Berry, Neil G. ; Benayoud, Farid ; Turner, Joseph D. ; Frohberger, Stefan J. ; Clare, Rachel H. ; Serwa, Remigiusz A. ; Webborn, Peter J. H. ; Murphy, Emma ; Qie, Li ; Leung, Suet C. ; Johnston, Kelly L. ; Cook, Darren A. N. ; Steven, Andrew ; Hubbard, Alasdair T. M. ; Archer, John ; Nixon, Gemma L. ; Hemingway, Janet ; Hoerauf, Achim ; Siu, Amy ; Taylor, Mark J. ; Ehrens, Alexandra ; Hong, W. David ; Struever, Dominique ; Ford, Louise ; Kavanagh, Stefan ; O’Neill, Paul M. ; Cassidy, Andrew ; Shiotani, Motohiro ; Tate, Edward W. ; Roberts, Adam P. ; Aljayyoussi, Ghaith ; Ward, Stephen A.
Significance:
Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) are neglected tropical diseases that cause severe disability and affect more than 157 million people globally. Current control efforts are hindered by the lack of a safe macrofilaricidal drug that can eliminate the parasitic adult nematodes safely. A clinically validated approach for delivering macrofilaricidal activity is to target the
Wolbachia
bacterial endosymbiont of the causative nematodes. This first-in-class and highly potent and specific anti-
Wolbachia
preclinical candidate molecule, AWZ1066S, has the potential to significantly impact current global onchocerciasis and lymphatic filariasis elimination programs and reduce elimination time frames from decades to years.